Expand VERU Menu
VERU MENU

VERU Latest Press Releases

-- May 22, 2024 --

Veru to Present at the Jefferies Global Healthcare Conference Globe Newswire 8:30 AM

-- May 15, 2024 --

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss Globe Newswire 8:30 AM

-- May 14, 2024 --

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week Globe Newswire 8:30 AM

-- May 8, 2024 --

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program Globe Newswire 6:30 AM

-- May 2, 2024 --

Veru to Present at the GLP-1 Based Therapeutics Summit Globe Newswire 8:30 AM

-- May 1, 2024 --

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 Globe Newswire 8:30 AM

-- April 30, 2024 --

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss Globe Newswire 8:30 AM

-- April 25, 2024 --

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 Globe Newswire 8:30 AM

-- April 1, 2024 --

Veru Announces Date of 2024 Annual Meeting of Shareholders Globe Newswire 4:05 PM

-- March 22, 2024 --

Veru Reschedules Annual Meeting of Shareholders Globe Newswire 4:05 PM

-- March 12, 2024 --

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss Globe Newswire 8:00 AM

-- February 27, 2024 --

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q Globe Newswire 7:15 PM

-- February 21, 2024 --

Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems Globe PR Wire 5:43 PM

-- February 20, 2024 --

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss Globe Newswire 8:30 AM

-- February 8, 2024 --

Veru Reports Fiscal 2024 First Quarter Financial Highlights Globe Newswire 6:30 AM

-- February 6, 2024 --

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs Globe Newswire 8:30 AM

-- January 31, 2024 --

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Globe Newswire 8:30 AM

-- January 25, 2024 --

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024 Globe Newswire 8:30 AM

-- January 8, 2024 --

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss Globe Newswire 8:30 AM